Cannabidiol for the treatment of psychosis in Parkinson's disease

“Mini-mental state”

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works

The FAB: A frontal assessment battery at bedside

Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000) · Neurology · doi:10.1212/wnl.55.11.1621 · Cited by 3,913 · see citing works

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481 · see citing works

The orphan receptor GPR55 is a novel cannabinoid receptor

Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568 · see citing works

Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors

Fénelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,035 · see citing works

Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Felder, C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., & Mitchell, R. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10492-6 · Cited by 900 · see citing works

Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro

Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763 · see citing works

Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group

Ravina, B., Marder, K., Fernandez, H. H., Friedman, J. H., McDonald, W., Murphy, D., Aarsland, D., Babcock, D., Cummings, J., Endicott, J., et al. (2007) · Movement Disorders · doi:10.1002/mds.21382 · Cited by 528 · see citing works

Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes.

Bech, P., Kastrup, M., & Rafaelsen, O. J. (1986) · PubMed · Cited by 466 · see citing works

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease

Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407 · see citing works

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402 · see citing works

Confiabilidade da "Entrevista Clínica Estruturada para o DSM-IV - Versão Clínica" traduzida para o português

Del-Ben, C. M., Vilela, J. A. A., Crippa, J. A. D. S., Hallak, J. E. C., Labate, C. M., & Zuardi, A. W. (2001) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462001000300008 · Cited by 386 · see citing works

Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra

French, E. D., Dillon, K. A., & Wu, X. (1997) · Neuroreport · doi:10.1097/00001756-199702100-00014 · Cited by 374 · see citing works

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties

García-Arencibia, M., González, S., de Lago, E., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.063 · Cited by 320 · see citing works

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

Williams, D. R., & Lees, A. J. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70146-0 · Cited by 302 · see citing works

Antipsychotic effect of cannabidiol.

Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995) · PubMed · Cited by 264 · see citing works

Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

Moreira, F. A., & Guimarães, F. S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.02.040 · Cited by 206 · see citing works

Cannabidiol monotherapy for treatment-resistant schizophrenia

Zuardi, A. W., Hallak, J. E. C., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. S. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060967 · Cited by 192 · see citing works

Effects of cannabidiol in animal models predictive of antipsychotic activity

Zuardi, A. W., Antunes Rodrigues, J., & Cunha, J. M. (1991) · Psychopharmacology · doi:10.1007/bf02244189 · Cited by 191 · see citing works

Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids

Diana, M., Melis, M., & Gessa, G. L. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00292.x · Cited by 152 · see citing works

Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid<i>in vivo</i>by mechanisms independent of the activation of cannabinoid, vanilloid TRPV₁and adenosine A_2Areceptors

Sagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., & Fernández‐Ruiz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05717.x · Cited by 147 · see citing works

Dorsolateral Prefrontal Cortex N-Acetylaspartate/Total Creatine (NAA/tCr) Loss in Male Recreational Cannabis Users

Hermann, D., Sartorius, A., Welzel, H., Walter, S., Skopp, G., Ende, G., & Mann, K. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.027 · Cited by 135 · see citing works

Increase in meso‐prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids

Diana, M., Melis, M., & Gessa, G. L. (1998) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1998.00292.x · Cited by 129 · see citing works

Psychotic Symptoms in Parkinson's Disease Patients with Dementia

Naimark, D. M. J., Jackson, E., Rockwell, E., & Jeste, D. V. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb00918.x · Cited by 97 · see citing works

A structured interview guide increases Brief Psychiatric Rating Scale reliability in raters with low clinical experience

Crippa, J. A. S., Sanches, R. F., Hallak, J. E. C., Loureiro, S. R., & Zuardi, A. W. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00185.x · Cited by 90 · see citing works

Responsibility of extrastriatal areas for the appearance of psychotic symptoms (Clinical and biochemical human post-mortem findings)

Birkmayer, W., & Riederer, P. F. (1975) · Journal of Neural Transmission · doi:10.1007/bf01663632 · Cited by 67 · see citing works

Psychosis in Parkinson’s disease

Thanvi, B. R., Lo, T. C. N., & Harsh, D. P. (2005) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.032029 · Cited by 55 · see citing works

Development and evaluation of the Parkinson Psychosis Questionnaire

Brandstädter, D., Spieker, S., Ulm, G., Siebert, U., Eichhorn, T. E., Krieg, J.-C., Oertel, W. H., & Eggert, K. M. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0816-x · Cited by 54 · see citing works

Factor structure of Bech's version of the Brief Psychiatric Rating Scale in Brazilian patients

Crippa, J. A. S., Sanches, R. F., Hallak, J. E. C., Loureiro, S. R., & Zuardi, A. W. (2002) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2002001000014 · Cited by 38 · see citing works

Cannabidiol as an antipsychotic agent

Leweke, F. M., Koethe, D., Gerth, C. W., Nolden, B. M., Schreiber, D., Gross, S., Schultze‐Lutter, F., Hellmich, M., & Klosterkötter, J. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.01.084 · Cited by 21 · see citing works

An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies

Iffland, K., & Grotenhermen, F. (2017) · Cannabis &amp; Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645 · see citing works

Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial

McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617 · see citing works

Cannabidiol: State of the art and new challenges for therapeutic applications

Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 625 · see citing works

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis

Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30401-8 · Cited by 564 · see citing works

Safety and side effects of cannabidiol, a Cannabis sativa constituent

Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · see citing works

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report

Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535 · see citing works

PI3K/AKT Signal Pathway: A Target of Natural Products in the Prevention and Treatment of Alzheimer’s Disease and Parkinson’s Disease

Long, H., Cheng, Y., Zhou, Z.-W., Luo, H., Wen, D., & Gao, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648636 · Cited by 504 · see citing works

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works

From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology

Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 484 · see citing works

Substance abuse and psychosis. The strange case of opioids.

Maremmani, A. G. I., Rovai, L., Rugani, F., Bacciardi, S., Dell’Osso, L., & Maremmani, I. (2014) · PubMed · Cited by 377 · see citing works

Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial

Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., & Crippa, J. A. S. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114550355 · Cited by 365 · see citing works

Phytocannabinoids as novel therapeutic agents in {CNS} disorders.

Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312 · see citing works

Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age

Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308 · see citing works

Cannabidiol: pharmacology and therapeutic targets

Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307 · see citing works

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306 · see citing works

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life

Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00259 · Cited by 294 · see citing works

Medical Use of Cannabinoids

Fraguas‐Sánchez, A. I., & Torres‐Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271 · see citing works

A systematic review of the antipsychotic properties of cannabidiol in humans

Iseger, T. A., & Bossong, M. G. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.033 · Cited by 261 · see citing works

Positive and Negative Effects of Cannabis and Cannabinoids on Health

Cohen, K., Weizman, A., & Weinstein, A. (2019) · Clinical Pharmacology &amp; Therapeutics · doi:10.1002/cpt.1381 · Cited by 255 · see citing works

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series

Chagas, M. H. N., Éckeli, Á. L., Zuardi, A. W., Pena-Pereira, M. A., Sobreira-Neto, M. A., Sobreira, E. T. A., Camilo, M. R., Bergamaschi, M. M., Schenck, C. H., Hallak, J. E. C., et al. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12179 · Cited by 253 · see citing works

Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science

Baron, E. P. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 256 · see citing works

A systematic review of cannabidiol dosing in clinical populations

Millar, S., Stone, N. L., Bellman, Z. D., Yates, A. S., England, T. J., & O’Sullivan, S. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14038 · Cited by 246 · see citing works

Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress

Booz, G. W. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.007 · Cited by 246 · see citing works

Cannabinoids: Therapeutic Use in Clinical Practice

Pagano, C., Navarra, G., Coppola, L., Avilia, G., Bifulco, M., & Laezza, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063344 · Cited by 250 · see citing works

Does Cannabidiol Protect Against Adverse Psychological Effects of THC?

Niesink, R. J. M., & van Laar, M. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00130 · Cited by 241 · see citing works

The psychiatric side-effects of rimonabant

Moreira, F. A., & Crippa, J. A. S. (2009) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462009000200012 · Cited by 235 · see citing works

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation

Waldo Zuardi, A., Alexandre S. Crippa, J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., & Silveira Guimaraes, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884681 · Cited by 222 · see citing works

Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light

Paparelli, A., di Forti, M., Morrison, P., & Murray, R. (2010) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00001 · Cited by 176 · see citing works

Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis

Wolf, S. A., Bick-Sander, A., Fabel, K., Leal-Galicia, P., Tauber, S., Ramirez-Rodriguez, G., Müller, A., Melnik, A., Waltinger, T. P., Ullrich, O., et al. (2010) · Cell Communication and Signaling · doi:10.1186/1478-811x-8-12 · Cited by 208 · see citing works

A behavioural comparison of acute and chronic Δ9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice

Long, L. E., Chesworth, R., Huang, X., McGregor, I. S., Arnold, J. C., & Karl, T. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990605 · Cited by 206 · see citing works

Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being

Morgan, C. J. A., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T. P., Warrington, P., Rupasinghe, I., Ramoutar, A., Tan, N., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711001322 · Cited by 195 · see citing works

Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination

Gonçalves, J., Rosado, T., Soares, S., Simão, A. Y., Caramelo, D., Luís, Â., Fernández, N., Barroso, M., Gallardo, E., & Duarte, A. P. (2019) · Medicines · doi:10.3390/medicines6010031 · Cited by 192 · see citing works

The Role of Phytochemicals in the Treatment and Prevention of Dementia

Howes, M. R., & Perry, E. K. (2011) · Drugs & Aging · doi:10.2165/11591310-000000000-00000 · Cited by 187 · see citing works

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Peres, F. F., Lima, A. C., Hallak, J. E. C., Crippa, J. A. S., Silva, R. H., & Abílio, V. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00482 · Cited by 160 · see citing works

Medicinal Plants and Dementia Therapy: Herbal Hopes for Brain Aging?

Perry, E. K., & Howes, M. R. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00202.x · Cited by 160 · see citing works

Endocannabinoid system dysfunction in mood and related disorders

Ashton, C. H., & Moore, P. B. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01687.x · Cited by 145 · see citing works

Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol

Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135 · see citing works

Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents

Fasinu, P. S., Phillips, S., ElSohly, M. A., & Walker, L. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1780 · Cited by 140 · see citing works

The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases

Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140 · see citing works

Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects

Marco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 136 · see citing works

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings

Elsaid, S., Kloiber, S. M., & Foll, B. L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.005 · Cited by 136 · see citing works

Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review

Cooray, R., Gupta, V. B., & Suphioglu, C. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02054-6 · Cited by 137 · see citing works

Cannabis Therapeutics and the Future of Neurology

Russo, E. B. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00051 · Cited by 132 · see citing works

Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease

Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129 · see citing works

Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans

Manini, A. F., Yiannoulos, G., Bergamaschi, M. M., Hernandez, S. H., Olmedo, R., Barnes, A. J., Winkel, G. H., Sinha, R., Jutras‐Aswad, D., Huestis, M. A., et al. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000118 · Cited by 127 · see citing works

Complementary Therapies in Parkinson Disease: a Review of Acupuncture, Tai Chi, Qi Gong, Yoga, and Cannabis

Deuel, L. M., & Seeberger, L. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00900-y · Cited by 131 · see citing works

Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone

Peball, M., Krismer, F., Knaus, H., Djamshidian, A., Werkmann, M., Carbone, F., Ellmerer, P., Heim, B., Marini, K., Valent, D., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25864 · Cited by 123 · see citing works

The therapeutic potential of cannabinoids for movement disorders

Kluger, B. M., Triolo, P. M., Jones, W. E., & Jankovic, J. J. (2015) · Movement Disorders · doi:10.1002/mds.26142 · Cited by 123 · see citing works

Cannabidiol as a suggested candidate for treatment of autism spectrum disorder

Poleg, S., Golubchik, P., Offen, D., & Weizman, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.08.030 · Cited by 123 · see citing works

Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines

Kuepper, R., Morrison, P. D., van Os, J., Murray, R. M., Kenis, G., & Henquet, C. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.031 · Cited by 116 · see citing works

Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience

Bhattacharyya, S., Falkenberg, I., Martín‐Santos, R., Atakan, Z., Crippa, J. A. S., Giampietro, V., Brammer, M. J., & McGuire, P. K. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.258 · Cited by 112 · see citing works

Efficacy and safety of medical cannabinoids in older subjects: A systematic review

van den Elsen, G. A. H., Ahmed, A. I. A., Lammers, M. W., Kramers, C., Verkes, R., van der Marck, M. A., & Rikkert, M. G. M. O. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.007 · Cited by 113 · see citing works

Cannabidiol as a potential treatment for psychosis

Davies, C., & Bhattacharyya, S. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319881916 · Cited by 113 · see citing works

Cannabidiol for neurodegenerative disorders: A comprehensive review

Bhunia, S., Kolishetti, N., Yndart, A., Vashist, A., & Nair, M. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989717 · Cited by 115 · see citing works

Cannabinoids in Parkinson's Disease

Bassi, M. S., Sancesario, A., Morace, R., Centonze, D., & Iezzi, E. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0002 · Cited by 109 · see citing works

Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders

Kaul, M., Zee, P. C., & Sahni, A. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01013-w · Cited by 109 · see citing works

Use of cannabidiol (CBD) for the treatment of chronic pain

Urits, I., Gress, K. L., Charipova, K., Habib, K., Lee, D. M., Lee, C. S., Jung, J. W., Kassem, H., Cornett, E. M., Paladini, A., et al. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.06.004 · Cited by 104 · see citing works

Cannabidiol as a potential treatment for psychosis

Schubart, C. D., Sommer, I. E., Fusar‐Poli, P., de Witte, L. D., Kahn, R. S., & Boks, M. P. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.11.002 · Cited by 100 · see citing works

The therapeutic role of Cannabidiol in mental health: a systematic review

Khan, R. A., Naveed, S., Mian, N., Fida, A., Raafey, M. A., & Aedma, K. K. (2020) · Journal of Cannabis Research · doi:10.1186/s42238-019-0012-y · Cited by 97 · see citing works

Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action

Pereira, M. D. S., da-Silva, C. A., Guimarães, F. S., & Bel, E. A. D. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.06.013 · Cited by 95 · see citing works

Clinical uses of cannabis and cannabinoids in the United States

Levinsohn, E. A., & Hill, K. P. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116717 · Cited by 92 · see citing works

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

Arnold, J. C., McCartney, D., Suraev, A. S., & McGregor, I. S. (2022) · Clinical and Translational Science · doi:10.1111/cts.13425 · Cited by 90 · see citing works

Cannabidiol does not display drug abuse potential in mice behavior

Viudez‐Martínez, A., García‐Gutiérrez, M. S., Medrano-Relinque, J., Navarrón, C. M., Navarrete, F., & Manzanares, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0032-8 · Cited by 90 · see citing works

Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders

Fagherazzi, E. V., Garcia, V. A., Maurmann, N., Bervanger, T., Halmenschlager, L. H., Busato, S. B., Hallak, J. E., Zuardi, A. W., Crippa, J. A., & Schröder, N. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2449-3 · Cited by 87 · see citing works

Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects

Pauli, C. S., Conroy, M., Heuvel, B. D. V., & Park, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00063 · Cited by 88 · see citing works

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview

Mandolini, G. M., Lazzaretti, M., Pigoni, A., Oldani, L., Delvecchio, G., & Brambilla, P. (2018) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000239 · Cited by 89 · see citing works

Uso terapêutico dos canabinoides em psiquiatria

Crippa, J. A. S., Zuardi, A. W., & Hallak, J. E. C. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500009 · Cited by 85 · see citing works

Metabolic Syndrome: An Important Risk Factor for Parkinson’s Disease

Zhang, P., & Tian, B. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/729194 · Cited by 84 · see citing works

Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review

SANTOS, R. G. D., Hallak, J. E. C., & Crippa, J. A. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57369-0_3 · Cited by 82 · see citing works

Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats

Chagas, M. H. N., Crippa, J. A. S., Zuardi, A. W., Hallak, J. E. C., Machado‐de‐Sousa, J. P., Hirotsu, C., Maia, L. O., Tufik, S. B., & Andersen, M. L. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112474524 · Cited by 81 · see citing works

Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania

Valvassori, S. S., Elias, G., de Souza, B., Petronilho, F., Dal-Pizzol, F., Kapczinski, F., Trzesniak, C., Tumas, V., Dursun, S., Nisihara Chagas, M. H., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109106925 · Cited by 80 · see citing works

Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function

Gruber, S. A., Sagar, K. A., Dahlgren, M. K., Racine, M. T., Smith, R. T., & Lukas, S. E. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00355 · Cited by 79 · see citing works

Effects of Cannabis in Parkinson’s Disease: A Systematic Review and Meta-Analysis

Urbi, B., Corbett, J., Hughes, I. P., Owusu, M. A., Thorning, S., Broadley, S., Sabet, A., & Heshmat, S. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212923 · Cited by 80 · see citing works

Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats

Peres, F. F., Levin, R. R., Suiama, M. A., Diana, M. C., Gouvêa, D. A., de Almeida, V., Santos, C. M., Lungato, L., Zuardi, A. W., Hallak, J. E. C., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00343 · Cited by 77 · see citing works

Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders

Navarrete, F., García‐Gutiérrez, M. S., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.626010 · Cited by 78 · see citing works

Acute and Non-acute Effects of Cannabis on Human Memory Function: A Critical Review of Neuroimaging Studies

Bossong, M. G., Jager, G., Bhattacharyya, S., & Allen, P. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990436 · Cited by 73 · see citing works

Treatment using cannabidiol in a horse with mechanical allodynia

Ellis, K. L., & Contino, E. K. (2019) · Equine Veterinary Education · doi:10.1111/eve.13168 · Cited by 74 · see citing works

Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice

Gomes, F. V., Bel, E. A. D., & Guimarães, F. S. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.005 · Cited by 74 · see citing works

Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain

Levin, R. R., Peres, F. F., de Almeida, V., Calzavara, M. B., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., & Abílio, V. C. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00010 · Cited by 74 · see citing works

Parkinson disease psychosis: from phenomenology to neurobiological mechanisms

Pagonabarraga, J., Bejr-Kasem, H., Martinez-Horta, S., & Kulisevsky, J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-023-00918-8 · Cited by 69 · see citing works

Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study

Leehey, M. A., Liu, Y., Hart, F., Epstein, C. H., Cook, M., Sillau, S., Klawitter, J., Newman, H., Sempio, C., Forman, L., et al. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0068 · Cited by 69 · see citing works

Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease

Giuliano, C., Francavilla, M., Ongari, G., Petese, A., Ghezzi, C., Rossini, N., Blandini, F., & Cerri, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168920 · Cited by 69 · see citing works

Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson’s disease

Celorrio, M., Fernández‐Suárez, D., Rojo-Bustamante, E., Echeverry‐Alzate, V., Ramírez, M. J., Hillard, C. J., López‐Moreno, J. A., Maldonado, R. J., Oyarzábal, J., Franco, R., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.06.010 · Cited by 68 · see citing works

Review: Cannabinoids as Medicinals

Khalsa, J. H., Bunt, G. C., Blum, K., Maggirwar, S. B., Galanter, M. S., & Potenza, M. N. (2022) · Current Addiction Reports · doi:10.1007/s40429-022-00438-3 · Cited by 72 · see citing works

Cannabidiol attenuates aggressive behavior induced by social isolation in mice: Involvement of 5-HT1A and CB1 receptors

dos Santos, A. H., Lisboa, S. F. D. S., Sonego, A. B., Coutinho, D., Gomes, F. V., & Guimarães, F. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109637 · Cited by 67 · see citing works

What can we learn about schizophrenia from studying the human model, drug‐induced psychosis?

Murray, R. M., Paparelli, A., Morrison, P. D., Marconi, A., & Forti, M. D. (2013) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32177 · Cited by 66 · see citing works

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?

Crippa, J. A. S., Hallak, J. E. C., Zuardi, A. W., Guimarães, F. S., Tumas, V., & SANTOS, R. G. D. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00982-6 · Cited by 66 · see citing works

In-tube solid-phase microextraction with a dummy molecularly imprinted monolithic capillary coupled to ultra-performance liquid chromatography-tandem mass spectrometry to determine cannabinoids in plasma samples

Marchioni, C., Vieira, T. M., Crotti, A. E. M., Crippa, J. A. S., & Queiroz, M. E. C. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.11.017 · Cited by 65 · see citing works

Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review

Singh, K., Bhushan, B., Chanchal, D. K., Sharma, S. K., Rani, K., Yadav, M. K., Porwal, P., Kumar, S., Sharma, A., Virmani, T., et al. (2023) · Behavioural Neurology · doi:10.1155/2023/8825358 · Cited by 71 · see citing works

Self-Reported Efficacy of Cannabis and Other Complementary Medicine Modalities by Parkinson’s Disease Patients in Colorado

Finseth, T. A., Hedeman, J. L., Brown, R. P., Johnson, K. I., Binder, M. S., & Kluger, B. M. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/874849 · Cited by 62 · see citing works

Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research

Sagar, K. A., & Gruber, S. A. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1460334 · Cited by 62 · see citing works

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice

Sonego, A. B., Gomes, F. V., Bel, E. A. D., & Guimarães, F. S. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.04.042 · Cited by 61 · see citing works

Cannabidiol and brain function: current knowledge and future perspectives

Schouten, M., Dalle, S., Mantini, D., & Koppo, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1328885 · Cited by 61 · see citing works

Quality of Life and a Surveillant Endocannabinoid System

Reis, R. A. D. M., Isaac, A. R., Freitas, H. R., de Almeida, M. M., Schuck, P. F., Ferreira, G. C., Andrade‐da‐Costa, B. L. D. S., & Trevenzoli, I. H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.747229 · Cited by 60 · see citing works

Characteristics and Patterns of Marijuana Use in Community‐Dwelling Older Adults

Reynolds, I. R., Fixen, D. R., Parnes, B. L., Lum, H. D., Shanbhag, P., Church, S. D., Linnebur, S. A., & Orosz, G. M. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15507 · Cited by 57 · see citing works

Cannabis in Parkinson’s Disease: The Patients’ View

Yenilmez, F., Fründt, O., Hidding, U., & Buhmann, C. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202260 · Cited by 59 · see citing works

The therapeutic potential of purified cannabidiol

O’Sullivan, S. E., Jensen, S. S., Nikolajsen, G. N., Bruun, H. Z., Bhuller, R., & Hoeng, J. (2023) · Journal of Cannabis Research · doi:10.1186/s42238-023-00186-9 · Cited by 56 · see citing works

Cannabinoids and Schizophrenia: Risks and Therapeutic Potential

Manseau, M. W., & GOFF, D. C. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0382-6 · Cited by 56 · see citing works

Even High Doses of Oral Cannabidiol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102–112; DOI: 10.1089/can.2015.0004

Grotenhermen, F., Russo, E. B., & Zuardi, A. W. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0036 · Cited by 56 · see citing works

Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia

Peres, F. F., Diana, M. C., Levin, R. R., Suiama, M. A., de Almeida, V., Vendramini, A. M., Santos, C. M., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00901 · Cited by 52 · see citing works

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?

Crippa, J. A. S., Hallak, J. E. C., Zuardi, A. W., Guimarães, F. S., Tumas, V., & SANTOS, R. G. D. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00982-6 · Cited by 66 · see citing works

P.3.c.023 Cannabidiol for the treatment of psychosis in Parkinson's disease

Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Pinto, J. P., Chagas, M. H. N., Rodrigues, G. R., Dursun, S. M., & Tumas, V. (2008) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(08)70608-4 · Cited by 1 · see citing works

Cannabis and psychosis: is there a role for Cannabidiol in the treatment of psychosis in young cannabis users?

Mota, P. M. P. C., Macedo, P., & Macedo, S. (2020) · International Journal of Psychiatry Research · doi:10.33545/26648962.2020.v2.i2a.29

A Doença de Parkinson e o uso do Canabidiol

Karolyne Vitoria, E. G. E. A. (2021) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

Cannabidiol as a potential treatment for psychosis

Davies, C., & Bhattacharyya, S. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319881916 · Cited by 113 · see citing works